Absci Q2 2025 net loss $30.6M; raises $64M in July; Almirall collaboration expands

Absci Corp

2025-Q2 EPS reported -$0.45 revenue$1,772,000

Q2 2025 revenue $0.6M (down from $1.3M YoY); net loss $30.6M vs $24.8M prior year.
Cash, equivalents, and ST investments $117.5M at June 30; raised ~$64M in July, extending runway into H1 2028.
Expanded Almirall AI drug discovery collaboration: second target elected, potential up to $650M in milestones across two programs.
ABS-101 (anti-TL1A) Phase 1 interim readout expected H2 2025; ABS-201 (anti-PRLR) Phase 1/2a start early 2026.
AMD strategic collaboration ongoing with $20M equity investment in Jan 2025; platform scaling using AMD Instinct accelerators.

item 9.01item 2.02item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.